Similar articles

• Phase II trials in journal of clinical oncology.

  Cannistra SA. Cannistra SA. J Clin Oncol. 2009 Jul 1;27(19):3073-6. doi: 10.1200/JCO.2009.23.1811. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451415 No abstract available.
• [Urologic Oncology Study Society. Promotor and facilitator of uro-oncologic clinical research].

  Rexer H, Krege S. Rexer H, et al. Urologe A. 2007 Sep;46(9):1306-13. doi: 10.1007/s00120-007-1506-3. Urologe A. 2007. PMID: 17701155 German. No abstract available.
• [Off-label use in oncology. Quackery or progress?].

  Rebscher H. Rebscher H. MMW Fortschr Med. 2002 Oct 10;144(41):25-6. MMW Fortschr Med. 2002. PMID: 12593414 German. No abstract available.
• Improving the design of phase II trials of cytostatic anticancer agents.

  Stone A, Wheeler C, Barge A. Stone A, et al. Contemp Clin Trials. 2007 Feb;28(2):138-45. doi: 10.1016/j.cct.2006.05.009. Epub 2006 Jul 14. Contemp Clin Trials. 2007. PMID: 16843736 Review.
• SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.

  Mills DA, Fekrazad HM, Verschraegen CF. Mills DA, et al. Curr Opin Investig Drugs. 2008 Jun;9(6):647-57. Curr Opin Investig Drugs. 2008. PMID: 18516764 Review.